MedTrace Logo

Influence of BCG on TDaP-IPV Vaccination

NCT02771782 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2016-10-13

No results posted yet for this study

Summary

This study has three purposes:

To investigate whether the immune response to pertussis is increased when TDaP-IPV is given together with BCG vaccine, compared to when it is given alone.

To investigate whether BCG vaccination modulates the immune response to non vaccine target antigens (i.e., antigens/pathogens not used in the vaccine itself).

To investigate whether TDaP-IPV vaccination modulates the immune response to non vaccine target antigens.

Conditions

Interventions

BIOLOGICAL

BCG vaccine (SSI)

BIOLOGICAL

TDaP-IPV vaccine

Sponsors & Collaborators

  • University of Southern Denmark

    collaborator OTHER

  • Radboud University Medical Center

    lead OTHER

Principal Investigators

  • Mihai Netea, Prof. Dr. · Radboud University Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-01-31
Primary Completion
2016-07-31
Completion
2017-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02771782 on ClinicalTrials.gov